In Vitro Sensitivity to Chemotherapy-Induced Apoptosis in CD2^+ve and CD2^-ve Childhood T-All

Adriaansen, H.J., te Boekhorst, P.A., Hagemeijer, A.M., van der Schoot, C.E., Delwel, H.R. & van Dongen, J.J. (1993). Acute myeloid leukemia M4 with bone marrow eosinophilia (M4Eo) and inv(16)(pl3q22) exhibits a specific immunophenotype with CD2 expression.Blood, 81, 3043–51.PubMedGoogle Scholar

Béné, M.C., Castoldi, G., Knapp, W., Ludwig, W.D., Matutes, E., Orfao, A. & van’t Veer, M.B. (1995). Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL).Leukemia, 9, 1783–6.PubMedGoogle Scholar

Creutzig, U., Harbott, J., Sperling, C., Ritter, J., Zimmermann, M., Löffler, H., Riehm, H., Schellong, G.& Ludwig, W.D. (1995). Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87.Blood, 86, 3097–108.PubMedGoogle Scholar

Dumont, C., Deas, O., Mollereau, B., Hebib, C., Giovino Barry, V., Bernard, A., Hirsch, F., Charpentier, B.& Senik, A. (1998). Potent apoptotic signaling and subsequent unresponsiveness induced by a single CD2 mAb (BTI-322) in activated human peripheral T cells.J Immunol 160,3797–804.PubMedGoogle Scholar

Houghton, J.A. (1999). Apoptosis and drug response.Curr Opin Oncol, 11, 475–81.PubMedCrossRefGoogle Scholar

Ida, H. & Anderson, P. (1998). Activation-induced NK cell death triggered by CD2 stimulation.Eur J Immunol28, 1292–300.PubMedCrossRefGoogle Scholar

Karawajew, L., Ruppert, V., Wuchter, C., Kösser, A., Schrappe, M., Dörken, B. & Ludwig, W.D. (2000). Inhibition of in vitro spontaneous apoptosis by IL-7 correlates with Bcl-2 up-regulation, cortical/mature immunophenotype, and better early cytoreduction of childhood T-cell acute lymphoblastic leukemia.Bloody96, 297–306.Google Scholar

Kaufmann, S.H.& Earnshaw, W.C. (2000). Induction of apoptosis by cancer chemotherapy.Exp Cell Res, 256,42–9.PubMedCrossRefGoogle Scholar

Niehues, T., Kapaun, P., Harms, D.O., Burdach, S., Kramm, C., Korholz, D., Janka Schaub, G. & Gobel, U. (1999). A classification based on T cell selection- related phenotypes identifies a subgroup of childhood T-ALL with favorable outcome in the COALL studies.Leukemia, 13, 614–7.PubMedCrossRefGoogle Scholar

Prokop, A., Wieder, T., Sturm, I., Essmann, F., Seeger, K., Wuchter, C., Ludwig, W.D., Henze, G., Dörken, B. & Daniel, P.T. (2000). Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo.Leukemia, 14, 1606–13.PubMedCrossRefGoogle Scholar

Reiter, A., Schrappe, M., Ludwig, W.D., Hiddemann, W., Sauter, S., Henze, G., Zimmermann, M., Lampert, F., Havers, W., Niethammer, D.& et al. (1994). Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86.Blood, 84, 3122–33.PubMedGoogle Scholar

Salomons, G.S., Smets, L.A., Verwijs Janssen, M., Hart, A.A., Haarman, E.G., Kaspers, G.J., Wering, E.V., Der Does Van Den Berg, A.V.& Kamps, W.A.(1999) Bcl-2 family members in childhood acute lymphoblastic leukemia: relationships with features at presentation, in vitro and in vivo drug response and long-term clinical outcome.Leukemia, 13,1574–80.PubMedCrossRefGoogle Scholar

Sturm, I., Papadopoulos, S., Hillebrand, T., Benter, T., Luck, H.J., Wolff, G., Dörken, B., Daniel, P.T. (2000). Impaired BAX protein expression in breast cancer: mutational analysis of the BAX and the p53 gene. Int J Cancer, 87, 517–21PubMedCrossRefGoogle Scholar

Uckun, F.M., Gaynon, P.S., Sensel, M.G., Nachman, J., Trigg, M.E., Steinherz, P.G., Hutchinson, R., Bostrom, B.C., Sather, H.N. & Reaman, G.H. (1997a). Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: a Children’s Cancer Group study.JClin Oncol, 15, 2214–21.Google Scholar

Uckun, F.M., Sensel, M.G., Sun, L., Steinherz, P.G., Trigg, M.E., Heerema, N.A., Sather, H.N., Reaman, G.H.& Gaynon, P.S. (1998). Biology and treatment of childhood T-lineage acute lymphoblastic leukemia.Bloody 91,735–46.Google Scholar

Uckun, F.M., Steinherz, P.G., Sather, H., Trigg, M., Arthur, D., Tubergen, D., Gaynon, P. & Reaman, G. (1996). CD2 antigen expression on leukemic cells as a predictor of event-free survival after chemotherapy for T-lineage acute lymphoblastic leukemia: a Children’s Cancer Group study.Blood, 88, 4288–95.PubMedGoogle Scholar

Uckun, F.M., Yang, Z., Sather, H., Steinherz, P., Nachman, J., Bostrom, B., Crotty, L., Sarquis, M., Ek, O., Zeren, T., Tubergen, D., Reaman, G. & Gaynon, P. (1997b). Cellular expression of antiapoptotic BCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: a Children’s Cancer Group Study.Bloody89, 3769–77.Google Scholar

Wuchter, C., Karawajew, L., Ruppert, V., Büchner, T., Schoch, C., Haferlach, T., Ratei, R., Dörken, B. & Ludwig, W.D. (1999). Clinical significance of CD95, Bcl- 2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics.Leukemia, 13, 1943–53.PubMedCrossRefGoogle Scholar

Wuchter, C., Karawajew, L., Ruppert, V., Schrappe, M., Harbott, J., Ratei, R., Dorken, B.& Ludwig, W.D. (2000). Constitutive expression levels of CD95 and Bcl-2 as well as CD95 function and spontaneous apoptosis in vitro do not predict the response to induction chemotherapy and relapse rate in childhood acute lymphoblastic leukaemia.Br J Haematol, 110,154–60.PubMedCrossRefGoogle Scholar